101 related articles for article (PubMed ID: 23744711)
1. Primary human non-small cell lung and pancreatic tumorgraft models--utility and applications in drug discovery and tumor biology.
Calles A; Rubio-Viqueira B; Hidalgo M
Curr Protoc Pharmacol; 2013 Jun; Chapter 14():Unit 14.26. PubMed ID: 23744711
[TBL] [Abstract][Full Text] [Related]
2. Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy.
Lee HW; Lee JI; Lee SJ; Cho HJ; Song HJ; Jeong DE; Seo YJ; Shin S; Joung JG; Kwon YJ; Choi YL; Park WY; Lee HM; Seol HJ; Shim YM; Joo KM; Nam DH
Clin Cancer Res; 2015 Mar; 21(5):1172-82. PubMed ID: 25549722
[TBL] [Abstract][Full Text] [Related]
3. Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling.
Sandercock AM; Rust S; Guillard S; Sachsenmeier KF; Holoweckyj N; Hay C; Flynn M; Huang Q; Yan K; Herpers B; Price LS; Soden J; Freeth J; Jermutus L; Hollingsworth R; Minter R
Mol Cancer; 2015 Jul; 14():147. PubMed ID: 26227951
[TBL] [Abstract][Full Text] [Related]
4. Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy?
Merk J; Rolff J; Becker M; Leschber G; Fichtner I
Eur J Cardiothorac Surg; 2009 Sep; 36(3):454-9. PubMed ID: 19502076
[TBL] [Abstract][Full Text] [Related]
5. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
Zhang J; Zhang L; Su X; Li M; Xie L; Malchers F; Fan S; Yin X; Xu Y; Liu K; Dong Z; Zhu G; Qian Z; Tang L; Schöttle J; Zhan P; Ji Q; Kilgour E; Smith PD; Brooks AN; Thomas RK; Gavine PR
Clin Cancer Res; 2012 Dec; 18(24):6658-67. PubMed ID: 23082000
[TBL] [Abstract][Full Text] [Related]
6. Mouse models in squamous cell lung cancer: impact for drug discovery.
Singh AP; Adrianzen Herrera D; Zhang Y; Perez-Soler R; Cheng H
Expert Opin Drug Discov; 2018 Apr; 13(4):347-358. PubMed ID: 29394493
[TBL] [Abstract][Full Text] [Related]
7. Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy?
Merk J; Rolff J; Dorn C; Leschber G; Fichtner I
Eur J Cardiothorac Surg; 2011 Jul; 40(1):e29-33. PubMed ID: 21420313
[TBL] [Abstract][Full Text] [Related]
8. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response.
Gao H; Korn JM; Ferretti S; Monahan JE; Wang Y; Singh M; Zhang C; Schnell C; Yang G; Zhang Y; Balbin OA; Barbe S; Cai H; Casey F; Chatterjee S; Chiang DY; Chuai S; Cogan SM; Collins SD; Dammassa E; Ebel N; Embry M; Green J; Kauffmann A; Kowal C; Leary RJ; Lehar J; Liang Y; Loo A; Lorenzana E; Robert McDonald E; McLaughlin ME; Merkin J; Meyer R; Naylor TL; Patawaran M; Reddy A; Röelli C; Ruddy DA; Salangsang F; Santacroce F; Singh AP; Tang Y; Tinetto W; Tobler S; Velazquez R; Venkatesan K; Von Arx F; Wang HQ; Wang Z; Wiesmann M; Wyss D; Xu F; Bitter H; Atadja P; Lees E; Hofmann F; Li E; Keen N; Cozens R; Jensen MR; Pryer NK; Williams JA; Sellers WR
Nat Med; 2015 Nov; 21(11):1318-25. PubMed ID: 26479923
[TBL] [Abstract][Full Text] [Related]
9. Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery.
Ruggeri BA; Camp F; Miknyoczki S
Biochem Pharmacol; 2014 Jan; 87(1):150-61. PubMed ID: 23817077
[TBL] [Abstract][Full Text] [Related]
10. From mice to men: GEMMs as trial patients for new NSCLC therapies.
Hayes SA; Hudson AL; Clarke SJ; Molloy MP; Howell VM
Semin Cell Dev Biol; 2014 Mar; 27():118-27. PubMed ID: 24718320
[TBL] [Abstract][Full Text] [Related]
11. Advances towards the design and development of personalized non-small-cell lung cancer drug therapy.
Vari S; Pilotto S; Maugeri-Saccà M; Ciuffreda L; Cesta Incani U; Falcone I; Del Curatolo A; Ceribelli A; Gelibter A; De Maria R; Tortora G; Cognetti F; Bria E; Milella M
Expert Opin Drug Discov; 2013 Nov; 8(11):1381-97. PubMed ID: 24088065
[TBL] [Abstract][Full Text] [Related]
12. Original triazine inductor of new specific molecular targets, with antitumor activity against nonsmall cell lung cancer.
Moreau D; Jacquot C; Tsita P; Chinou I; Tomasoni C; Juge M; Antoniadou-Vyza E; Martignat L; Pineau A; Roussakis C
Int J Cancer; 2008 Dec; 123(11):2676-83. PubMed ID: 18798255
[TBL] [Abstract][Full Text] [Related]
13. Gene expression analysis in biomarker research and early drug development using function tested reverse transcription quantitative real-time PCR assays.
Lohmann S; Herold A; Bergauer T; Belousov A; Betzl G; Demario M; Dietrich M; Luistro L; Poignée-Heger M; Schostack K; Simcox M; Walch H; Yin X; Zhong H; Weisser M
Methods; 2013 Jan; 59(1):10-9. PubMed ID: 22796720
[TBL] [Abstract][Full Text] [Related]
14. Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer.
Hammer S; Sommer A; Fichtner I; Becker M; Rolff J; Merk J; Klar U; Hoffmann J
Clin Cancer Res; 2010 Mar; 16(5):1452-65. PubMed ID: 20179216
[TBL] [Abstract][Full Text] [Related]
15. Erlotinib antitumor activity in non-small cell lung cancer models is independent of HER1 and HER2 overexpression.
Friess T; Scheuer W; Hasmann M
Anticancer Res; 2006; 26(5A):3505-12. PubMed ID: 17094474
[TBL] [Abstract][Full Text] [Related]
16. Prediction of chemotherapeutic effect on postoperative recurrence by in vitro anticancer drug sensitivity testing in non-small cell lung cancer patients.
Higashiyama M; Oda K; Okami J; Maeda J; Kodama K; Imamura F; Minamikawa K; Takano T; Kobayashi H
Lung Cancer; 2010 Jun; 68(3):472-7. PubMed ID: 19660825
[TBL] [Abstract][Full Text] [Related]
17. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemotherapy and the role of chemotherapy resistance testing for stage I non-small cell lung cancer.
D'Amato TA
Thorac Surg Clin; 2007 May; 17(2):287-99. PubMed ID: 17626407
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer.
Fahham D; Weiss ID; Abraham M; Beider K; Hanna W; Shlomai Z; Eizenberg O; Zamir G; Izhar U; Shapira OM; Peled A; Wald O
J Thorac Cardiovasc Surg; 2012 Nov; 144(5):1167-1175.e1. PubMed ID: 22925564
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
